Regis Healthcare shares down 2% as CEO resigns

Dr Mellors will step down as CEO after more than six years in the role.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Regis Healthcare CEO has resigned and is pursuing an opportunity outside the aged care sector.
  • Despite being up 20% for the year, Regis shares have been on a wild ride, climbing 53% to $9.22 before a September funding update triggered a 35% sell-off.
  • With a CEO search underway and government funding reforms still bedding down, the market appears cautious, focused on execution, labour cost control, and delivery of FY26 earnings.

Shares in Regis Healthcare Ltd (ASX: REG) are down 2% after the aged care operator announced the resignation of Chief Executive Officer Dr Linda Mellors.

In an ASX release, Regis confirmed that Dr Mellors will step down after more than six years in the role, having decided to pursue an opportunity outside the aged care sector. She will remain in her position during a six-month notice period while the board conducts an executive search and manages a transition of responsibilities.

While leadership changes can prompt short-term uncertainty, today's share price reaction also needs to be viewed in the context of a volatile year for Regis investors.

A man packs up a box of belongings at his desk as he prepares to leave the office.

Image source: Getty Images

A strong year with a sharp reversal

On the surface, Regis shares are still up about 20% year to date, having started the year around $6. However, that headline gain masks a much bumpier journey.

Earlier in 2025, optimism around Regis shares, powered by sector reform and operational improvements, drove the Regis share price up as much as 53%, peaking at $9.22. That rally came to an abrupt end on 22 September, when the company released a funding update outlining the impact of changes to government aged care funding models.

At the time, Regis revealed that increases under the Australian National Aged Care Classification (AN-ACC) framework would fall well short of expectations, largely due to reweighting across resident classifications. The announcement triggered a sharp reassessment by the market, with the share price falling around 35% back to $6, effectively wiping out the year's gains.

Why today's news matters

Against that backdrop, the resignation of the CEO introduces another layer of uncertainty. Dr Mellors led Regis through major industry upheavals, including the Royal Commission into Aged Care, the COVID-19 pandemic, and the rollout of the new Aged Care Act. The board acknowledged her role in stabilising and transforming the business, noting that Regis remains in a strong financial and operational position.

However, investors appear cautious about leadership change at a time when the company is still adjusting to funding pressures and wage cost increases across the sector.

What's next for Regis?

An executive search is now underway, and the company has emphasised continuity during the transition period. For shareholders, attention will likely return to how Regis navigates government funding reforms, manages labour costs, and delivers on its FY26 earnings outlook.

For now, the market reaction suggests investors are taking a "wait and see" approach, wary after September's funding shock, but still recognising the longer-term recovery story remains intact.

Motley Fool contributor Kevin Gandiya has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares before the end of July?

Here's what I expect from the beaten-down biotech stock next month.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Broker Notes

Up 1,250% in a year, why 4DMedical shares can keep charging higher

A top analyst forecasts more outperformance from the surging shares.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

Down 31%: Is there any chance of a rebound from ResMed shares?

The ASX healthcare share has lost 31% over the past 12 months.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

If I invested $5,000 in this ASX healthcare stock 12 months ago, I'd have over $67k today!

This ASX healthcare stock is bucking the trend.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Down 35% for the year, is it time to buy this beaten-down ASX biotech?

Stronger revenue numbers signal potential upside.

Read more »